Johnson & Johnson Accelerates Dual-Track Transformation: Strategic Restructuring and $1B DAC Platform Acquisition in June

　　【Pharmaceutical Network | Corporate News] Recent news reports that Andrew Burton, who has served at Johnson & Johnson MedTech for over a decade, has officially assumed the role of global head of DePuy Synthes’ orthopedics business under Johnson & Johnson.RobotAs the business leader, he will spearhead the formulation of the global robotics business strategy, integrating technology, data, and orthopedic diagnostic and therapeutic services to drive the progressive implementation of various innovative achievements from conceptualization to realization.
 

It is reported that Johnson & Johnson announced in October 2025 its plan to spin off its orthopedics business, DePuy Synthes, into an independent company, with the divestiture expected to be completed within the next 18 to 24 months. Despite the impending separation, Johnson & Johnson’s orthopedics division continues to expand. Currently, the company has 21 products launched in the U.S. market. Recently, it not only acquired radiofrequency tracking technology but also introduced Velys, a new AI-assisted navigation platform for hip surgery, in the United States.
 

The VELYS™ system is a key robotic platform for Johnson & Johnson Orthopaedics. It received FDA approval in 2021 for use in total knee arthroplasty (TKA). In June 2024, the system gained an additional indication for unicompartmental knee arthroplasty (UKA) in the United States, expanding its application from “total knee” to “minimally invasive unicompartmental” procedures.
 

Notably, in addition to Andrew Burton’s appointment as Global Head of Robotics for DePuy Synthes’ orthopedics business, Johnson & Johnson has announced a series of personnel changes as part of its major strategic realignment since 2026. On June 9, DePuy Synthes, the orthopedics subsidiary of Johnson & Johnson, announced that Paolo Di Vincenzo has officially assumed the role of Global President of Trauma, based in West Chester, Pennsylvania, USA.
 

According to available information, prior to joining Johnson & Johnson, Paolo Di Vincenzo served as President of Medtronic’s Neuromodulation business. His career path also includes tenures at Smith & Nephew, BD (Becton, Dickinson and Company), and Roche, spanning three major business segments—neuromodulation, wound care, and orthopedic trauma—and encompassing practical experience in both emerging markets and mature markets in Europe and the United States.
 

On May 1, Johnson & Johnson officially announced the appointment of Ryan Cools as Vice President of Investor Relations (IR), effective May 7, 2026. Since joining Johnson & Johnson in 2002, Ryan has held roles across multiple core functional areas, including Innovative Medicine, Research and Development, MedTech, and Supply Chain. For the past three years, he has served as Vice President of Finance and Chief Financial Officer for Johnson & Johnson Innovative Medicine’s Global R&D company, where he led strategic financial planning and capital allocation.
 

In May, Johnson & Johnson laid off 56 employees at its New Jersey headquarters. A spokesperson stated that the layoffs were directly related to the spin-off of its orthopedics business, aiming to address cost issues and improve operating profit margins.
 

While paving the way for “slimming down” and transformation through personnel and organizational changes, Johnson & Johnson is also positioning for the future through significant acquisitions. On June 8, Johnson & Johnson announced that it would acquire Firefly Bio for $1 billion in cash. According to the announcement, upon completion of the transaction, Firefly Bio’s independently developed Firelink™ Degrader Antibody Conjugate (DAC) platform will be integrated into Johnson & Johnson’s oncology R&D system, with a focus on drug development for pan-KRAS and other drivers of refractory solid tumors.
 

Overall, Johnson & Johnson has recently undertaken a series of profound personnel and organizational restructuring measures, along with significant acquisitions, primarily to prepare for the divestiture of its orthopedics business. Currently, this plan is advancing rapidly.
 

　　Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.